Smith & Nephew SNATS PE Ratio 2006-2018 | SNN

Current and historical p/e ratio for Smith & Nephew SNATS (SNN) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Smith & Nephew SNATS PE ratio as of November 14, 2018 is 0.00.
Smith & Nephew SNATS PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-11-15 36.55 inf
2018-06-30 37.53 0 0.00
2017-12-31 34.59 0 0.00
2017-06-30 34.20 0 0.00
2016-12-31 29.17 $0.36 81.04
2015-12-31 33.89 $0.59 57.43
2015-06-30 32.10 $0.79 40.63
2014-12-31 34.36 $1.13 30.52
2014-09-30 31.28 $1.13 27.78
2014-06-30 33.17 $1.16 28.49
2014-03-31 28.09 $1.25 22.51
2013-12-31 26.35 $1.23 21.45
2013-09-30 22.73 $1.18 19.20
2013-06-30 20.43 $1.22 16.80
2013-03-31 20.73 $1.59 13.05
2012-12-31 19.89 $1.63 12.19
2012-09-30 19.60 $1.63 12.04
2012-06-30 17.78 $1.63 10.92
2012-03-31 17.77 $1.31 13.55
2011-12-31 16.95 $1.30 13.04
2011-09-30 15.62 $1.40 11.19
2011-06-30 18.93 $1.40 13.56
2011-03-31 19.55 $1.36 14.33
2010-12-31 18.21 $1.38 13.24
2010-09-30 15.63 $1.26 12.44
2010-06-30 16.18 $1.24 13.01
2010-03-31 17.10 $1.20 14.20
2009-12-31 17.50 $1.06 16.45
2009-09-30 15.28 $1.04 14.75
2009-06-30 12.64 $0.91 13.93
2009-03-31 10.48 $0.87 12.02
2008-12-31 10.84 $0.84 12.90
2008-09-30 17.71 $0.80 22.03
2008-06-30 18.26 $0.68 27.02
2008-03-31 21.89 $0.68 32.19
2007-12-31 19.05 $0.68 27.84
2007-09-30 20.24 $0.76 26.49
2007-06-30 20.50 $0.77 26.55
2007-03-31 20.87 $0.76 27.60
2006-12-31 17.20 $1.44 11.91
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $16.007B $4.765B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $124.342B 19.06
Abbott Laboratories (ABT) United States $122.048B 24.73
Stryker (SYK) United States $62.796B 23.67
Boston Scientific (BSX) United States $50.730B 25.64
Baxter (BAX) United States $33.541B 21.66
Zimmer Biomet Holdings (ZBH) United States $23.031B 14.94
ResMed (RMD) United States $14.492B 27.64
Canopy Growth (CGC) Canada $8.934B 0.00
Perrigo (PRGO) Ireland $8.884B 13.48
Bio-Rad Laboratories (BIO) United States $8.054B 51.50
Aurora Cannabis (ACB) Canada $6.462B 35.26
Hill-Rom Holdings (HRC) United States $6.201B 19.66
Haemonetics (HAE) United States $5.495B 48.33
Insulet (PODD) United States $4.770B 0.00
ICU Medical (ICUI) United States $4.529B 25.23
Hutchison China MediTech (HCM) China $4.274B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.987B 0.00
Agios Pharmaceuticals (AGIO) United States $3.869B 0.00
Neogen (NEOG) United States $3.219B 48.74
National Vision Holdings (EYE) United States $3.101B 61.33
NuVasive (NUVA) United States $2.972B 27.65
Aphria (APHA) $2.572B 0.00
Quidel (QDEL) United States $2.478B 32.30
NxStage Medical (NXTM) United States $1.924B 0.00
Phibro Animal Health (PAHC) United States $1.476B 20.89
AtriCure (ATRC) United States $1.174B 0.00
Cardiovascular Systems (CSII) United States $1.015B 1462.50
VAREX IMAGING (VREX) United States $0.992B 19.93
Meridian Bioscience (VIVO) United States $0.827B 26.35
PetIQ (PETQ) United States $0.803B 22.83
OraSure Technologies (OSUR) United States $0.793B 44.65
Surmodics (SRDX) United States $0.776B 118.55
Eagle Pharmaceuticals (EGRX) United States $0.755B 24.22
Cerus (CERS) United States $0.719B 0.00
MacroGenics (MGNX) United States $0.710B 0.00
Omeros (OMER) United States $0.623B 0.00
Lantheus Holdings (LNTH) United States $0.590B 18.27
Owens & Minor (OMI) United States $0.558B 6.31
Insys Therapeutics (INSY) United States $0.542B 0.00
LeMaitre Vascular (LMAT) United States $0.518B 25.45
NanoString Technologies (NSTG) United States $0.481B 0.00
TG Therapeutics (TGTX) United States $0.438B 0.00
Evolus (EOLS) United States $0.399B 0.00
Quanterix (QTRX) United States $0.359B 0.00
Utah Medical Products (UTMD) United States $0.327B 21.12
Cytosorbents (CTSO) United States $0.302B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.255B 0.00
Surface Oncology (SURF) United States $0.226B 0.00
Rockwell Medical (RMTI) United States $0.211B 0.00
BioLife Solutions (BLFS) United States $0.206B 278.75
Bovie Medical (BVX) United States $0.201B 0.00
Chimerix (CMRX) United States $0.161B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.148B 0.00
Fonar (FONR) United States $0.139B 6.96
Chembio Diagnostics (CEMI) United States $0.104B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.081B 0.00
United-Guardian (UG) United States $0.079B 16.63
Female Health (VERU) United States $0.079B 0.00
Trinity Biotech (TRIB) Ireland $0.077B 24.40
Oramed Pharmaceuticals (ORMP) Israel $0.070B 0.00
InfuSystems Holdings (INFU) United States $0.067B 0.00
CAS Medical Systems (CASM) United States $0.056B 0.00
Neurotrope (NTRP) United States $0.050B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Capricor Therapeutics (CAPR) United States $0.028B 0.00
Myomo (MYO) United States $0.025B 0.00
Valeritas Holdings (VLRX) United States $0.021B 0.00
Senestech (SNES) United States $0.019B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.019B 0.00
Cellectar Biosciences (CLRB) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.000B 0.00